The President has signed a federal funding package incorporating substantive reforms to pharmacy benefit manager (PBM) practices within Medicare Part D. This development, occurring this week, grants the Centers for Medicare & Medicaid Services (CMS) enhanced authority to enforce "reasonable and relevant" pharmacy contract standards, monitor network access, and prohibit compensation linked to manufacturer list prices. For independent pharmacies, particularly those in rural or underserved regions, these measures address longstanding concerns over reimbursement adequacy, DIR fees, and exclusionary contracting.

While implementation requires rulemaking, the reforms signal a shift toward greater federal oversight, potentially mitigating economic pressures that have challenged independent operators.

Key Provisions and Their Scope

CMS is directed to establish concrete definitions for "reasonable and relevant" terms previously subject to limited enforcement. This encompasses reimbursement methodologies aligned with acquisition costs (such as NADAC benchmarks plus dispensing fees), transparency in DIR adjustments, and criteria preventing de facto network barriers through unviable economics.

Ongoing monitoring will cover payment disparities, inclusion/exclusion patterns, and beneficiary access metrics. Violations may result in civil penalties, corrective actions, or plan sanctions.

Of particular note is the introduction of "essential retail pharmacies," intended to safeguard outlets critical for access in vulnerable areas. Such pharmacies—often independents serving rural populations or dual-eligibles (Medicare and Medicaid)—will benefit from procedural protections against termination and equitable reimbursement parity.

Additionally, PBM compensation models based on list prices (e.g., percentages of WAC or AWP) are barred in Part D, promoting structures like fixed fees decoupled from pricing volatility. Plan sponsors assume responsibility for compliance.

These provisions apply exclusively to Part D, leaving commercial and Medicaid markets unaffected for now, though precedents may influence broader practices.

Detailed Timeline for Implementation

The reforms outline a clear progression, emphasizing prompt action:

• Immediate Phase (February 2026)

  CMS issues initial guidance on data reporting requirements for payments, networks, and access.

• Spring 2026

  Notice of Proposed Rulemaking (NPRM) published in the Federal Register, inviting public comments to refine standards.

• Fourth Quarter 2026

  Final rules adopted, incorporating feedback.

• Calendar Year 2027

  PBMs and plan sponsors incorporate changes into bid submissions.

• January 1, 2028

  Full compliance mandatory for new and renewed contracts, with penalties for deviations.

Pharmacies are advised to align preparations with this cadence, particularly ahead of contract renewals.

Practical Implications for Independent Pharmacies

Analyses suggest potential reimbursement improvements of 10-15% for independents under rigorous enforcement, alongside reduced termination risks. Negotiations gain leverage through reference to emerging CMS criteria, and administrative remedies supplant protracted arbitrations.

The law does not overhaul PBM practices across all markets, does not directly regulate employer-sponsored commercial plans, and does not eliminate reimbursement pressure overnight. The reform is Part D–specific and depends heavily on future CMS rulemaking. But this legislature does represent a structural turning point for pharmacies. he federal government is moving from indirect oversight to a more defined regulatory framework governing PBM–pharmacy relationships in Medicare Part D. The practical impact will depend on how CMS implements these provisions, but the direction is clear: greater scrutiny of reimbursement fairness, network access, and PBM financial incentives.

Stakeholders should begin reviewing current Part D contracts and reimbursement structures, network admission and termination practices, compensation arrangements tied to pricing metrics, and documentation supporting commercial reasonableness and access considerations. Entities that rely heavily on Part D volume should anticipate increased federal visibility into contracting and payment practices.

We are closely monitoring rulemaking and guidance and are available to assist clients in assessing risk exposure and preparing for implementation. You may email MDRXLaw at info@mdrxlaw.com or call us at 212.668.0200 with any questions.